Agree with both a massive re-rate and a watchful eye by pharma Philley.
A partnering into one of the concurrent 3 trials on the PTX-200 or the pilot(s) trials (proposed to shortly commence) would give us just that. This ‘ insurance ‘ of a partnership would facilitate in the longevity of all trials going the distance towards commercialisation.
Wishful thinking? Perhaps.
Luck to holders.
PTX Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
